<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00462696</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000540537</org_study_id>
    <secondary_id>IB-2005-37</secondary_id>
    <secondary_id>INCA-RECF0144</secondary_id>
    <secondary_id>IB-ISNA</secondary_id>
    <nct_id>NCT00462696</nct_id>
  </id_info>
  <brief_title>MRI in Evaluating Early Response to Chemotherapy in Women Receiving Chemotherapy for Infiltrating Breast Cancer</brief_title>
  <official_title>Study Evaluating the Contribution of MRI for the Evaluation of Early Response to Neoadjuvant Chemotherapy in Patients With Infiltrative Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Bergonié</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Diagnostic procedures, such as magnetic resonance imaging (MRI), may help in&#xD;
      learning how well chemotherapy works to kill breast cancer cells and allow doctors to plan&#xD;
      better treatment. Drugs used in chemotherapy, such as epirubicin and docetaxel, may stop the&#xD;
      growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving&#xD;
      chemotherapy before surgery may make the tumor smaller and reduce the amount of normal tissue&#xD;
      that needs to be removed.&#xD;
&#xD;
      PURPOSE: This clinical trial is studying MRI in evaluating early response to chemotherapy in&#xD;
      women receiving chemotherapy for infiltrating breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Evaluate the feasibility (reproducibility and repeatability) of MRI for assessing tumor&#xD;
           vascularity in women receiving neoadjuvant chemotherapy for infiltrative breast cancer.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Compare the results obtained by semiquantitative measurement of vascularization (MRI) vs&#xD;
           traditional empirical evaluation.&#xD;
&#xD;
        -  Evaluate the MRI accuracy for the measurement of tumoral volume after completion of&#xD;
           chemotherapy.&#xD;
&#xD;
      OUTLINE: This is an uncontrolled, nonrandomized study.&#xD;
&#xD;
      Patients receive neoadjuvant chemotherapy comprising epirubicin hydrochloride IV and&#xD;
      docetaxel IV on day 1. Treatment repeats every 3 weeks for 6 courses in the absence of&#xD;
      disease progression or unacceptable toxicity.&#xD;
&#xD;
      Patients undergo dynamic-contrast MRI before treatment, 3 weeks after the first course of&#xD;
      chemotherapy, and 3 weeks after the completion of chemotherapy. They also undergo a bilateral&#xD;
      mammogram and sonography and clinical examination.&#xD;
&#xD;
      Within 22-35 days after completion of chemotherapy, patients undergo breast-conserving&#xD;
      surgical resection of tumor and lymph nodes or mastectomy.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 30 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2006</start_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <primary_purpose>Diagnostic</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Reproducibility and repeatability of MRI</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Results of MRI vs mammogram</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRI accuracy</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Breast Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>docetaxel</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>epirubicin hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>conventional surgery</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>dynamic contrast-enhanced magnetic resonance imaging</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>neoadjuvant therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>radiomammography</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed infiltrative breast cancer meeting 1 of the following&#xD;
             criteria:&#xD;
&#xD;
               -  Operable T2 or T3, M0 disease&#xD;
&#xD;
               -  Locally advanced disease (T4a, b, or c)&#xD;
&#xD;
                    -  No T4d disease&#xD;
&#xD;
          -  Indication for neoadjuvant chemotherapy before breast-conserving surgery&#xD;
&#xD;
               -  No desire by patient for complete mastectomy&#xD;
&#xD;
          -  No overexpression of HER-2&#xD;
&#xD;
          -  No multifocal tumor&#xD;
&#xD;
          -  Hormone receptor status not specified&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Female&#xD;
&#xD;
          -  Menopausal status not specified&#xD;
&#xD;
          -  Life expectancy &gt; 6 months&#xD;
&#xD;
          -  No contraindication to MRI with contrast, including any of the following:&#xD;
&#xD;
               -  Claustrophobia&#xD;
&#xD;
               -  Prior major allergies&#xD;
&#xD;
               -  Cardiac pacemaker&#xD;
&#xD;
               -  Surgical clips&#xD;
&#xD;
               -  Certain cardiac valves&#xD;
&#xD;
               -  Sunken or hollow filters&#xD;
&#xD;
               -  Implanted pump&#xD;
&#xD;
               -  Cochlear implants&#xD;
&#xD;
               -  Metallic foreign body (intra-ocular)&#xD;
&#xD;
          -  No contraindication to chemotherapy or surgery&#xD;
&#xD;
          -  No other serious condition that would preclude study therapy&#xD;
&#xD;
          -  No other uncontrolled medical condition, including any of the following:&#xD;
&#xD;
               -  Thyroid disease&#xD;
&#xD;
               -  Neuropsychiatric disease&#xD;
&#xD;
               -  Infection&#xD;
&#xD;
               -  Insufficient coronary capacity&#xD;
&#xD;
               -  NYHA class III-IV heart disease&#xD;
&#xD;
          -  No HIV positivity&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No prior chemotherapy, radiotherapy, or surgery for ipsilateral breast cancer&#xD;
&#xD;
          -  No prior biopsy of tumor before MRI&#xD;
&#xD;
          -  No MRI at another center within the past 15 days&#xD;
&#xD;
          -  No participation in another investigational study of anticancer therapy within the&#xD;
             past 30 days&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fabienne Valentin, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Institut Bergonié</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institut Bergonie</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2008</verification_date>
  <study_first_submitted>April 18, 2007</study_first_submitted>
  <study_first_submitted_qc>April 18, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 19, 2007</study_first_posted>
  <last_update_submitted>May 12, 2011</last_update_submitted>
  <last_update_submitted_qc>May 12, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 13, 2011</last_update_posted>
  <keyword>stage II breast cancer</keyword>
  <keyword>stage IIIA breast cancer</keyword>
  <keyword>stage IIIB breast cancer</keyword>
  <keyword>stage IIIC breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Epirubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

